FRNM — Freenome, Inc.

Is FRNM overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Overbought As of August 19, 2026

Freenome, Inc. (FRNM) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Diagnostics & Research) last closed at $13.63.

See all overbought Healthcare stocks →

AI analysis

Freenome, Inc. operates a multiomics liquid-biopsy platform positioned to benefit from increased demand for earlier cancer detection and AI-enabled diagnostic workflows. The company’s technological differentiation and potential for strategic partnerships support a pathway to commercial revenue if clinical validation and payer coverage are secured. Near-term performance depends on clinical readouts, reimbursement progress, and execution of lab and sales infrastructure; financing needs and commercialization execution are the main constraints. Sector developments that validate diagnostic adoption are favorable, but competition, regulatory complexity, and sensitivity/specificity outcomes create material execution risk. Overall scenarios range from successful market entry with accelerating revenue to slower adoption requiring additional capital and strategic alternatives.

Key factors

  • Addressable market tailwinds for oncology diagnostics and early cancer screening as procedures and AI-enabled diagnostic tools gain adoption
  • Proprietary multiomics and machine-learning platform that can differentiate the company from single-modality competitors if clinical validity/utility is demonstrated
  • Potential commercial and partnership opportunities as payers and providers seek earlier, more accurate screening tools—readthrough from recent diagnostic wins in the sector
  • Recent sector catalysts (AI-enabled diagnostics regulatory clearances) that validate demand for advanced diagnostic tools and could accelerate adoption
  • If Freenome can demonstrate reproducible sensitivity/specificity and obtain favorable reimbursement, revenue scaling is possible given high long-term per-patient value
  • Current market mood is balanced with selective interest in growth/diagnostic names, reducing immediate downside from broad selloffs

Risks

  • Clinical validation risk: failure to achieve reproducible sensitivity/specificity or clinical utility could materially impair adoption
  • Reimbursement and payer risk: limited or delayed coverage decisions would restrict commercial uptake and revenue visibility
  • Capital and cash-runway risk: as a development-stage diagnostics company, ongoing R&D and commercialization spend could require equity financing at dilutive terms
  • Competitive pressure from established and deep-pocketed players (e.g., Guardant, Exact Sciences, Illumina/Grail legacy assets) with overlapping product roadmaps
  • Regulatory and enforcement risk for digital-health adjacent companies that could increase compliance costs or limit data-driven business models
  • Market perception and commercial execution risk: slow provider adoption, lab-network buildout challenges, or negative study readouts could depress sentiment

See today's live rating, score and targets

Members see the live hourly rating for FRNM — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.